In this interview podcast, Dwarkesh Patel interviews Jacob Kimmel, president and co-founder of New Limit, about the science of epigenetic reprogramming for anti-aging purposes. They discuss why evolution didn't optimize for longevity, covering hazard rates, kin selection, and optimization constraints. Kimmel explains New Limit's approach to reversing aging by epigenetically reprogramming cells using transcription factors, addressing potential challenges and the need for AI models to navigate the complexity of the genome. The conversation explores delivery methods for these therapies, the potential for long-term benefits, and the economic implications of extending healthy lifespans, including the role of pharmaceutical companies and the future of healthcare spending.
Sign in to continue reading, translating and more.
Continue